Health insurer Cigna has abandoned its attempt to acquire rival Humana due to a failure to agree on the price. The potential deal, which was revealed in November 2023, aimed to create a combined company exceeding $140 billion in value but faced substantial antitrust scrutiny. This development underscores the ongoing challenges and regulatory scrutiny faced by the health insurance industry in pursuing consolidation. The failure of the deal comes six years after regulators blocked similar mega-mergers in the sector.
In response to the failed acquisition, Cigna has announced plans to repurchase an additional $10 billion of its own shares, expanding the total repurchase program to $11.3 billion. This move reflects Cigna's focus on returning value to shareholders through direct investment in the company. Cigna CEO David Cordani emphasised the company's commitment to delivering high-quality care, affordability, and improved health outcomes. The company is also reportedly exploring the potential sale of its Medicare Advantage business, which could address antitrust concerns and potentially pave the way for future merger attempts with Humana.
Analysts suggest that the failed merger could have provided the combined entity with greater scale to compete against larger players like UnitedHealth and CVS Health. However, concerns over significant overlap in their Medicare businesses, particularly Humana's dominant position, raised antitrust issues.
Given the history of antitrust challenges in the industry, experts anticipate potential regulatory hurdles in any future merger attempts between Cigna and Humana. The sale of Cigna's Medicare Advantage business is seen as a strategic move to mitigate antitrust concerns and improve the prospects of a future combination with Humana.
Click here to read the original news story.